Allergy Immunotherapy in Istanbul

What Is Allergy Immunotherapy?

Allergen immunotherapy is a treatment approach that uses selected allergens to modify the response to clinically relevant allergy triggers. For respiratory allergy, it may be delivered by injection under the skin or by a preparation placed under the tongue. The aim is to improve allergy control over time, rather than simply provide immediate relief during a symptomatic episode.

People sometimes call it an allergy vaccine, but that name can be misleading if it suggests one injection provides instant protection. Assessment, product selection, repeated treatment and review are central to the process. When enquiring at Istanbul Allergy, explain which symptoms or diagnosis you want help with. The team can confirm the appropriate consultation arrangements before you make decisions about a particular preparation or treatment schedule.

Which Allergic Conditions Does This Page Cover?

This page focuses on immunotherapy for respiratory allergy, particularly allergic rhinitis with or without allergic eye symptoms and selected circumstances involving allergic asthma. It does not describe a universal treatment for every rash, intolerance or positive allergy test. Venom immunotherapy for insect allergy and oral immunotherapy for food allergy have different clinical pathways and should not be confused with treatment for inhaled allergens.

If your main concern involves a food, visit our Oral Immunotherapy in Turkey page. For a suspected insect-sting reaction, ask the team about the available assessment scope rather than assuming a respiratory programme is suitable. Naming the problem clearly helps distinguish the service you are seeking and the evidence that should inform the consultation. Treatment for one allergic condition is not automatic treatment for another.

How Is Immunotherapy Different from Symptom Medication?

Symptom medicines and immunotherapy have different roles. An antihistamine or prescribed nasal treatment may be part of controlling current symptoms, while allergen immunotherapy is considered as a longer-term option directed at an identified allergen. AIT may be discussed when symptom control, medicine burden and patient preferences make it a relevant choice; it is not a reason to abandon an effective existing plan without review.

Bring a list of medicines, how often they are used and what benefit or side effects you notice. Explain whether the main problem is persistent symptoms, a difficult season or a wish to review long-term options. Your doctor can assess the current treatment before discussing alternatives. Do not stop an inhaler, nasal medicine or other prescription because an immunotherapy appointment has been booked. Changes should follow individual medical advice.

Confirming That an Allergen Is Relevant to Your Symptoms

Treatment selection requires a connection between the history, exposure and evidence of sensitisation. Skin prick testing or specific IgE testing can support an assessment, but an isolated positive result is not a complete explanation for every symptom. The timing and circumstances of symptoms help determine which findings matter clinically.

Tell the doctor about patterns at home, work, school and during travel. Include months when symptoms improve, contact with animals and changes after moving. Bring previous test reports with their dates and methods where available. If a report lists many allergens, do not assume every item should be placed in a treatment mixture. Ask which allergen is thought to drive the symptoms and why treating it is expected to address your particular concerns.

Pollen Allergy: Seasonal Symptoms and Treatment Planning

For pollen-related symptoms, discuss the season, where you spend time and the effect on sleep, study or work. A record of symptomatic months can help the clinician interpret testing in context. If you live abroad, describe your usual environment rather than only the exposures encountered on a short visit to Istanbul. Treatment should address the patient’s relevant allergy pattern, not the location of the consultation alone.

Ask which pollen is being considered, what product is proposed and when treatment would begin relative to the season. Some preparations use seasonal schedules and others differ. The timing needs to follow the relevant product and clinical plan. Do not assume that starting during a trip provides immediate protection for the following week, or that the name “pollen allergy” identifies one interchangeable product for all grasses, weeds and trees.

House Dust Mite Allergy and Year-Round Concerns

House dust mite allergy can be associated with persistent rhinitis and, in selected patients, allergic asthma. EAACI has produced specific guidance for mite-driven allergic asthma, illustrating that suitability depends on the clinical condition and product rather than a positive mite result alone. An asthma assessment is particularly important where breathing symptoms accompany nasal allergy.

Explain the main symptoms, their effect on daily life and the treatment you have already tried. Ask whether the proposed approach addresses nasal symptoms, asthma-related concerns or both. Your doctor should clarify how progress would be judged and what existing treatment continues. A mite diagnosis does not guarantee that every preparation, route or age indication is appropriate. Confirm the actual product and service availability before arranging a treatment-related visit.

Animal and Mould Allergies: Why the Evidence Needs Specific Review

Evidence is not equally strong for every animal allergen or mould. The EAACI User’s Guide describes limitations in these areas, including differences between cat and dog evidence and the narrower evidence base for mould extracts such as Alternaria. The word “immunotherapy” should not imply that all products have the same support.

If you are enquiring about cat, dog or mould allergy, identify the exposure and the symptoms that occur. Ask which extract is available, what evidence supports its use and what practical changes remain important. Do not interpret treatment as a guarantee that unrestricted exposure will become symptom-free. A consultation can clarify options even when the conclusion is that a proposed product is not appropriate, evidence is limited or a different management plan should be prioritised.

Who Might Be Considered for Immunotherapy?

Assessment brings together the diagnosis, impact of symptoms, previous management, product-specific evidence and the patient’s preferences. A person who is able to attend repeated appointments may consider different options from someone who lives far away. The ability to follow instructions and maintain a longer-term plan matters alongside the clinical findings.

Ask what makes immunotherapy a relevant option in your case and what alternatives exist. Describe your priorities: fewer difficult seasons, less disruption to daily activities or a review of medicine use. Explain practical limits such as school, work, travel and caregiving responsibilities. A recommendation should fit the actual patient rather than an ideal timetable. An enquiry or test result does not itself confirm suitability, and a decision to continue standard management can be reasonable.

Asthma Control and Other Factors That Affect Suitability

Severe, unstable or uncontrolled asthma is an important concern when considering allergen immunotherapy. Your clinician needs to assess breathing symptoms and treatment stability before a programme is started or continued. Guidance also considers other medical conditions and medicines that could affect the response to a serious reaction or its treatment.

Report asthma attacks, recent worsening, urgent visits, current inhalers and any relevant cardiovascular treatment. Do not stop a medicine to try to become eligible. Tell the team about pregnancy, plans for pregnancy and important changes in health so the treatment decision can be reviewed. The appropriate conclusion may be to investigate further, improve control first or select another approach. A previously agreed plan still needs reassessment when circumstances change.

Injection Immunotherapy: What SCIT Involves

Subcutaneous immunotherapy, or SCIT, gives allergen injections through a clinical programme with build-up and maintenance stages. Injections should be administered in an appropriate healthcare setting with staff and equipment to manage reactions; this is not a home injection programme. Local redness or swelling can occur, and systemic reactions, including anaphylaxis, are possible.

Before starting, ask how appointments are organised and how much time to allow for treatment and observation. Confirm who prescribes the preparation, who administers it and how changes are documented. If your plan involves care in more than one country, establish those responsibilities before treatment begins. An appointment to discuss injections should not be interpreted as confirmation that a specific injection schedule can be completed during a short stay.

Build-up, Maintenance and Observation for Injection Treatment

The schedule depends on the preparation, protocol and patient’s clinical situation. Ask for the proposed build-up pattern, maintenance frequency and observation instructions in writing. Traditional and accelerated schedules should not be treated as interchangeable choices made solely to fit a holiday. If an accelerated option is discussed, request a clear explanation of availability, supervision and the reasons for selecting it.

At each visit, tell the team about changes since the previous appointment, including reactions and changes in health or medication. Do not leave before completing the required observation. Ask what to do if symptoms develop later and how to report a reaction before the next appointment. If a visit is missed, the responsible service must decide how the schedule resumes; do not assume the previous amount can simply be repeated anywhere.

Sublingual Immunotherapy: Tablets and Liquid Preparations

Sublingual immunotherapy, or SLIT, uses an allergen preparation under the tongue. Tablets and liquid extracts are not automatically dose-equivalent or interchangeable. Product-specific indications and instructions matter. For SLIT tablets, professional guidance calls for an initial dose in a supervised medical setting; subsequent treatment follows the prescribed product and clinical plan.

Confirm whether the proposed preparation is a tablet or liquid product, which allergen it contains and the age range and indication relevant to the patient. Local availability and authorisation need checking in Turkey and in the country where treatment will continue. A US-listed tablet is not proof of the same access elsewhere. Ask for the exact product name and instructions rather than relying on a general label such as “drops” or “allergy spray”.

Is Sublingual Immunotherapy the Same as a Nasal Spray?

No. A prescribed nasal spray for symptom management is not automatically an immunotherapy preparation. Sublingual means under the tongue, whereas a nasal medicine is administered through the nose. Patients may use informal names for treatments, but the product, route and intended purpose should be clear before anything is started.

If you already have a product, bring the packaging or an accurate photograph of the label. Ask the clinician to explain what it does, how it relates to the proposed plan and whether it should continue. Never move a preparation from one route to another or assume that different products with similar branding can be substituted. Clear naming also helps when care is discussed across languages or transferred between services.

Comparing Injection and Sublingual Immunotherapy

There is no single best route for every patient. The relevant allergen, product evidence, clinical history, age and practical commitments should guide the discussion. FDA information describes specific sublingual tablet products, while European guidance emphasises evaluating the evidence for the actual product proposed. Neither a convenient route nor a familiar brand replaces that assessment.

Use the comparison below to organise your questions rather than choose treatment independently. Ask what is available for the allergen being treated, what supervision applies and how the plan will be sustained. In particular, travelling patients need a clear answer about who will provide treatment after returning home. A route that seems easier initially may be unsuitable if supply or follow-up cannot be maintained.

How Long Does Allergy Immunotherapy Usually Last?

A course is generally measured in years, not days. Many injection programmes continue for around three to five years; the exact plan depends on response and the treatment being used. Duration and review points should be discussed before starting, rather than treating a first appointment or the end of build-up as the completion of care.

Ask about three separate timelines: initial assessment, establishment of the proposed schedule and the longer-term course. Clarify which milestones are provisional and what information is needed before a firmer plan can be given. If the patient is moving, studying abroad or travelling frequently, raise that early. Do not assume a multi-year treatment can be compressed because only a short visit to Istanbul is possible.

Expected Benefits and How Progress Should Be Reviewed

A systematic review supporting the EAACI rhinitis guideline found benefits for symptoms, medication scores and combined outcomes across the studied immunotherapy approaches. Those findings do not establish an identical response for every preparation or patient. Study populations, allergens and treatment conditions differ.

Agree how your own progress will be assessed. Record meaningful changes such as symptom burden, medicine use, sleep and interference with activities, while noting changes in exposure. One unusually easy pollen season or a holiday away from an allergen may complicate interpretation. Ask when a formal review will occur and what would lead the doctor to continue, modify or stop the programme. Repeated testing alone is not a complete description of how you are functioning in daily life.

Long-Term Benefit, Relapse and Prevention Claims

Some patients retain benefit after a completed course, but a permanent cure cannot be promised. EAACI recommends at least three years of treatment when aiming for long-term benefit in allergic rhinoconjunctivitis, with particularly strong long-term evidence for certain grass products. Evidence should still be interpreted for the proposed treatment rather than assumed across all allergens.

Claims about preventing asthma require the same care. EAACI prevention guidance addresses defined groups of children and adolescents with grass or birch pollen-related rhinitis; it is not a guarantee that any immunotherapy will prevent asthma in every child.

Ask the clinician to distinguish current symptom control, longer-term benefit after treatment and prevention of a different condition. These are separate outcomes. A sound decision explains which aim is supported for the patient’s circumstances and which uncertainties remain.

Risks, Side Effects and Emergency Planning

Discuss route-specific reactions before treatment is agreed. Injection programmes can cause local or systemic reactions. Sublingual products can cause symptoms in the mouth and throat, and serious reactions are possible. Product warnings, medical history and the ability to follow the treatment plan need review. A route described as convenient should not be interpreted as risk-free.

Ask how symptoms should be recognised, what the prescribed response plan is and who to contact after a non-urgent reaction. Adrenaline is first-line emergency treatment for anaphylaxis; do not substitute a routine clinic message or antihistamine for the appropriate emergency response. Follow your prescribed plan and seek urgent local help when a serious reaction occurs.

If a reaction changes the next treatment step, obtain instructions from the responsible clinical team. Do not independently retry, increase or switch a preparation because the earlier symptoms have settled.

Swallowing Problems and Product-Specific SLIT Precautions

Certain SLIT tablet prescribing information lists a history of eosinophilic oesophagitis as a contraindication and warns about persistent swallowing or chest symptoms. The US ODACTRA label is one example of product-specific instructions, not a universal label for every preparation or a statement of Turkish availability.

Report swallowing problems, persistent digestive symptoms and relevant prior diagnoses during assessment. Ask how oral inflammation, dental procedures or other changes should be managed for the actual product prescribed. Do not ignore persistent symptoms or make your own substitution. The clinical team needs to review whether treatment remains appropriate and whether another assessment is needed. Instructions for one brand should not be transferred to a different tablet or liquid extract without medical confirmation.

Treatment Planning for Children and Adolescents

A child’s appointment should address symptoms, daily functioning and the practical ability to follow treatment. Age limits vary by product and clinical setting, so there is no single minimum age that should be applied to every route or allergen. Ask what evidence and instructions apply to the specific preparation proposed rather than using age alone to decide eligibility.

Include the child in a developmentally appropriate discussion. Talk about needle concerns, taste, school routines, caregivers and the responsibilities that would fall on the family. Adolescents should have room to explain their own priorities and questions. Confirm who will supervise any prescribed home treatment and how information is shared when caregivers change. A plan that is understood and feasible is more useful than one agreed without considering ordinary family life.

Allergy Immunotherapy Enquiries for Adults

Adults may be seeking better control after years of seasonal symptoms or a review of persistent allergy despite treatment. Explain the problem you most want to address, how symptoms affect daily life and what you have already tried. Bring previous test results and a current medication list. Ask whether the next step is to clarify diagnosis, optimise existing management or assess an immunotherapy option.

Istanbul Allergy accepts enquiries for adult and child consultations. Tell the team the patient’s age, diagnosis and relevant allergen so the appointment scope can be confirmed. For adults, employment, regular travel and other health conditions may shape the available choices. Do not assume that a convenient online consultation removes the need for examination or a supervised first treatment. Clinical and practical suitability both need discussion.

Missed Appointments, Illness and Changes in Routine

Before starting, obtain instructions about what to do when treatment is missed, the patient becomes unwell or a medicine changes. The response depends on the route, preparation, length of interruption and clinical circumstances. Do not use another patient’s timetable or a generic internet rule to decide how to resume. Ask whom to contact and what information the team needs.

Plan ahead for holidays, exams, work travel and relocation. If supply or attendance could be interrupted, discuss it before the problem occurs. Do not double a home amount or arrange an injection from an unfamiliar provider without an agreed transfer plan. Regular review should make it possible to report difficulties honestly. A sustainable schedule matters more than appearing to follow a plan that cannot be maintained safely.

Starting Treatment in Istanbul When You Live Abroad

Begin with a consultation enquiry rather than a promise to start a particular programme during a holiday. Provide the patient’s age, usual country of residence, main symptoms, relevant tests and proposed travel dates. The responsible clinician needs to consider where exposure occurs and how treatment would continue after the initial visit.

For injections, identify the qualified service that would administer subsequent treatment and whether it accepts the proposed preparation and documentation. For sublingual treatment, confirm lawful access, supply and supervision in the country where the patient will live. These arrangements must be confirmed by the services involved; a webpage cannot guarantee a cross-border transfer. If continuity cannot be established, ask whether another care option is more practical.

What Happens at the First Consultation?

The doctor will review the symptom pattern, existing diagnoses, previous investigations and current management. Be ready to explain what changes with season, environment or animal exposure. Bring complete reports with dates and methods where possible. A list of positive allergens without the surrounding clinical history may not answer the treatment question.

Ask what remains uncertain and whether further examination or testing is needed. If a treatment is proposed, request the product, route, goals, supervision and provisional scheduling. Confirm which services are included in the appointment fee. You should leave understanding the next step, even if that step is another assessment rather than immediate treatment. Our Allergy Testing page explains the broader investigation enquiries.

Online Consultation and Longer-Term Follow-up

An online consultation may help review history and records before travelling. It cannot administer an injection, perform skin testing or provide every examination required for a treatment decision. Ask what the appointment can address and confirm its date, time zone, fee and connection arrangements. A video booking does not guarantee that a preparation will be prescribed or that a supervised step can be omitted.

Follow-up can include selected remote discussions where appropriate, but the overall plan needs clear clinical responsibility. Agree how progress, symptoms and treatment changes will be reviewed. If local care is needed, establish the relevant service before starting. The Online Consultation page explains appointment preparation; Plan Your Visit provides a practical travel checklist.

What Affects the Cost of Allergy Immunotherapy in Turkey?

The total commitment can include assessment, investigations, product supply, supervised administration and review appointments. Different preparations and routes can have different practical and financial requirements. Ask for a clear explanation of the initial charge, what is included and which later services are separate. Confirm arrangements for delays, missed visits or changes in the proposed treatment.

For international patients, include repeated travel, accommodation and time away from work or school when considering feasibility. A low initial consultation fee does not describe the cost of a multi-year course. Ask about ongoing availability and how treatment would be paid for after returning home. No fixed package price is listed here because diagnosis, product selection and follow-up arrangements must first be clarified. Contact our team for current appointment and service information.

Making an Informed Decision with Your Clinician

A good treatment discussion should compare expected benefit, uncertainties, alternatives and treatment burden. Ask which allergen is being targeted, why it is relevant, what evidence supports the product and how your response will be measured. Request clarification when a general term such as “allergy vaccine” hides important differences between preparations or routes.

Before agreeing, confirm the attendance requirements, written instructions, reaction plan, review points and long-term supply arrangements. Explain any barrier that could prevent the plan from working in everyday life. Continuing symptom management, postponing treatment or obtaining further information are reasonable outcomes of an assessment. The aim is not to prescribe immunotherapy to everyone who enquires, but to identify an appropriate and practical plan for the patient.

YOUR QUESTIONS

Allergy Immunotherapy: Frequently Asked Questions

Scientific Sources & Further Reading

Product indications and availability vary by country. Overseas guidance and labels do not confirm Turkish access, individual suitability or identical treatment schedules.

1. EAACI: Allergen immunotherapy for allergic rhinoconjunctivitis — guideline (2018). ↗
2. AAAAI: Allergy shots — immunotherapy. ↗
3. AAAAI/ACAAI: Sublingual immunotherapy practice parameter (2017). ↗
4. FDA: Allergen extract sublingual tablets. ↗
5. EAACI: House dust mite-driven allergic asthma — immunotherapy guideline (2019). ↗
6. EAACI: Allergen Immunotherapy User’s Guide (2020). ↗
7. Dhami et al.: Allergen immunotherapy for allergic rhinoconjunctivitis — systematic review and meta-analysis (2017). ↗
8. FDA: ODACTRA prescribing information. Product-specific US document; not a statement of Turkish availability. ↗
9. EAACI: Prevention of allergy — allergen immunotherapy guideline. ↗
10. AAAAI: Allergy testing — patient information. ↗
11. AAAAI: Anaphylaxis — symptoms and treatment. ↗
12. CSACI: Immunotherapy manual — professional resources. ↗